Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01839396 · ClinicalTrials.gov registry record · NA
Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 313
- Enrollment target
NCT01839396 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 313 participants.
The verdict
NCT01839396, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 313 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced, levodopa-responsive bilateral Parkinson's disease (PD) which is not adequately controlled with medication.
Interventions
- DEVICE Deep Brain Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2013-05-17 |
| Est. Completion | 2022-12-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01839396
The ClinicalTrials.gov registry entry for NCT01839396 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Deep Brain Stimulation is the first listed.
NCT01839396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01839396 about?
NCT01839396 is a clinical study titled "Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease". The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced, levodopa-responsive bilateral Parkinson's disease (PD) which is not adequately controlled with medication.
What is the current status of trial NCT01839396?
This trial is currently completed. It is a NA study. The enrollment target is 313 participants. The study started on 2013-05-17. Estimated completion is 2022-12-05.
What interventions are being tested in trial NCT01839396?
The interventions under investigation include: Deep Brain Stimulation (DEVICE).
Who is sponsoring clinical trial NCT01839396?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.